Oral Semaglutide for the Treatment of Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease and Antipsychotic-Associated Weight Gain (AAWG) Not Responding to Metformin – A Case Series
Year: 2025
Type: article
Abstract: Prevention and treatment of type 2 diabetes and obesity are problematic for individuals with schizophrenia and other patients on antipsychotic therapy because atypical antipsychotics and mental distress themselves increase appetite, thus promoting subsequent body weight gain and deterioration of glycaemic control. Almost half of patients with schizophrenia have body mass index (BMI) ≥ 25- and 2.5-times higher risk of developing T2D compared to healthy individuals [1]. Antipsychotic (AP) drugs are the cornerstone treatment for schizophrenia and are commonly used for other psychiatric disorders. However, they are associated with severe metabolic adverse effects, including weight gain, dyslipidaemia, and insulin resistance [2]. Particularly, insulin resistance and type 2 diabetes mellitus (T2DM) induce Non-alcoholic fatty liver disease (NAFLD) onset, deterioration of liver inflammation/fibrosis, and development of hepatocellular carcinoma. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, accounting for approximately 25% of chronic liver disease cases worldwide [3].
Author: Subhash Saxena1*, Tanushree2, Anil Tambi3, Priya Mathur4, Navneet Saxena5
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6912052452
FWCI:
Cites:
Cited by:
Related to: